SuperworthVir Biotechnology EPS VIR
Diluted earnings per share by quarter and over the last twelve months, from 2018.
- Last 12 months, to Jun 30, 2026
- −$1.86
- Latest quarter, Q2 FY26
- $0.47
- Fiscal year 2025
- −$3.16
Vir Biotechnology's earnings per share was −$1.86 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was $0.47.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$3.16 | n/a |
| FY2024 | −$3.82 | n/a |
| FY2023 | −$4.59 | −220% |
| FY2022 | $3.81 | −2% |
| FY2021 | $3.89 | n/a |
| FY2020 | −$2.48 | n/a |
| FY2018 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.47 | n/a | −$1.86 | |
| Q1 FY26 | −$0.85 | n/a | −$3.13 | |
| Q4 FY25 | −$0.31 | n/a | −$3.16 | |
| Q3 FY25 | −$1.17 | n/a | −$3.61 | |
| Q2 FY25 | −$0.80 | n/a | −$4.00 | |
| Q1 FY25 | −$0.88 | n/a | −$4.22 | |
| Q4 FY24 | −$0.76 | n/a | −$3.82 | |
| Q3 FY24 | −$1.56 | n/a | −$3.92 | |
| Q2 FY24 | −$1.02 | n/a | −$3.58 | |
| Q1 FY24 | −$0.48 | n/a | −$4.01 | |
| Q4 FY23 | −$0.86 | n/a | −$4.59 | |
| Q3 FY23 | −$1.22 | −194% | −$4.49 |
Against its peers
Companies in Biotechnology nearest Vir Biotechnology's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| VIRVir Biotechnology | −$1.86 | |
| VCELVericel | $0.46 | +283% a year |
| ADMAAdma Biologics | $0.70 | −18% a year |
| MGTXMeiraGTx | $0.71 | |
| KRYSKrystal Biotech | $7.98 | +62% a year |
| RGENRepligen | $0.73 | |
| TECHBIO-TECHNE | $1.15 | +150% a year |
| HALOHalozyme Therapeutics | $3.35 | −23% a year |
| NBIXNeurocrine Biosciences | $6.82 | +102% a year |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| EXELExelixis | $3.18 | +53% a year |
| Peer median | $0.94 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Vir Biotechnology
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.